

QuickVue[®]

Results. Right. Now.


SARS Antigen



Test and Treat Today®!

- Identifies SARS-CoV-2 antigens in 10 minutes for better patient management decisions
- Accurate detection with direct anterior nares swab samples: 96.6% PPA and 99.3% NPA
- Simple workflow follows a similar format to CLIA-waved QuickVue assays, just sample, dip, and read
- Each kit contains everything needed to perform the test, including nasal swabs and Positive and Negative Controls
- Room temperature storage

Nasal swab procedure:



Comparison of QuickVue SARS Antigen Test and an authorized EUA Molecular Comparator Assay with Matched Anterior Nares Swabs*

Specimen Type	Number Tested	True Positive	False Positive	True Negative	False Negative	PPA%	NPA%	PPA 95% CI	NPA 95% CI
Fresh Specimens	138	30	1	106	1	96.8	99.1	83.8 to 99.4	94.9 to 99.8
Frozen Specimens	56	26	0	29	1	96.3	100	81.7 to 99.3	88.3 to 100
Combined Specimens	194	56	1	135	2	96.6	99.3	88.3 to 99.0	96.0 to 99.9

^{*}Please refer to the Package Insert for full study design and explanation.

The QuickVue SARS Antigen Test has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless authorization is terminated or revoked sooner.

